Form 8-K BALCHEM CORP For: Sep 27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 27, 2022
(Exact name of registrant as specified in its charter)
|
|
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (845 )
326-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
On September 29, 2022, Balchem Corporation (the “Company”) announced that James C. Hyde, Senior Vice President and General Manager, Human
Nutrition & Health, has notified the Company of his intent to retire from his role and that he will step down upon the appointment of his successor. Mr. Hyde is expected to stay on for a transition period and retire from the Company in 2023.
There are no material changes to Mr. Hyde’s compensatory arrangement as a result of his planned retirement from his current role.
Item 9.01 |
Financial Statements and Exhibits.
|
(d) |
Exhibits
|
Exhibit Number
|
Description
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
BALCHEM CORPORATION
|
|||
(Registrant)
|
|||
By:
|
/s/ Hatsuki Miyata
|
||
Hatsuki Miyata
|
|||
General Counsel and Secretary
|
|||
Date: September 29, 2022
|
ATTACHMENTS / EXHIBITS
XBRL TAXONOMY EXTENSION SCHEMA
XBRL TAXONOMY EXTENSION LABEL LINKBASE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Balchem Corporation Releases 2023 Sustainability Report
- Peking University Emerges Victorious in 2024 ASC Student Supercomputer Challenge Finals
- Semiconductor Tech Firm IceMOS Technology One of Only Ten Exceptional Exporters Honoured in UK Government’s Made in the UK, Sold to the World Awards
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!